Table 2. Phenome-wide association analysis (PheWAS) of 205 clinical variables with FGF19 or FGF21 serum levels (pg/mL).

	Direction of association	FGF19(P-value)	FGF21(P-value)
Anthropometric	Older age x higher FGF21	0.11095	0.00115
	Taller x higher FGF21	0.83335	0.02166
	Larger waist x higher FGF21	0.35547	0.03535
Disease	Diabetes x lower FGF19	0.00142	0.11761
	Hypertension x higher FGF21	0.48434	0.0037
	Liver fibrosis x lower FGF19	0.00506	0.93641
Diagnostic	Higher glucose* x higher FGF21	0.15621	0.00003
	Higher HbA1c x higher FGF21	0.1995	0.00188
	Lower LDL x higher FGF21	0.46145	0.0353
	Higher creatinine x higher FGF21	0.42198	0.01965
	Lower EGFR x higher FGF21	0.84129	0.00482
Medication	Metformin x lower FGF19	0.02677	0.44619
	Sulfonylurea x lower FGF19	0.02697	0.05797
	Insulin x higher FGF21	0.87188	0.04984
	ISA x lower FGF19	0.00984	0.49681
	ACE x higher FGF21	0.66932	0.00164
	Statins x higher FGF21	0.14334	0.00295
	Multiple meds x higher FGF21	0.48933	0.00266
	CCB x higher FGF21	0.95894	0.00389
	Salicylates x higher FGF21	0.80814	0.00954
	Potassium x higher FGF21	0.7106	0.01953

P-values were according to Wilcoxon rank sum test (categorical clinical variables or least-squared linear regression analysis (for continuous clinical variables). After Bonferonni corrections for multiple testing, only the association of higher glucose* with higher FGF21 remained significant. LDL: low density lipoprotein, EGFR: estimated glomerular filtration rate, ISA: insulin sensitizing agents other than metformin, ACE: ACE inhibitors, CCB: calcium channel blockers.